Exchange: NYSE·Updated 07:32 PM EDT

WST News

News
all
press releases
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
Zacks
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
Zacks
More News
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
VEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.
Zacks
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.
Zacks
Here's Why You Should Retain WAT Stock in Your Portfolio for Now
Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.
Zacks
West to Host Third-Quarter 2026 Conference Call
West to Host Third-Quarter 2026 Conference Call West to Host Third-Quarter 2026 Conference CallPR NewswireEXTON, Pa., Oct. 8, 2026EXTON, Pa., Oct. 8, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc.(NYSE: WST), a global leader in innovative solutions for injectable drug administration, today...
PR Newswire
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.
Zacks
BDX Expands U.S. Manufacturing With $19B Healthcare Investment
BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.
Zacks
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY's strong HSA growth, AI-driven efficiencies and raised fiscal 2027 outlook support momentum, though cybersecurity risks remain a concern.
Zacks
Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
VEEV's DQS cleans clinical trial data for over 1 million subjects across 1,000+ studies, expanding automation in clinical data management.
Zacks
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's broad product portfolio, global expansion and strategic M&A support growth, while tariffs and China pressures remain key risks.
Zacks

Advertisement|Remove ads.